sarcoma
A combination of doxorubicin and tumor necrosis factor alpha (TNFalpha) has been proven to be very effective in the perfusional treatment of advanced soft tissue limb sarcoma both in terms of tumor necrosis and limb conservative surgery rate.
A combination of doxorubicin and <span class="gene" id="17203757-1-33-60">tumor necrosis factor alpha</span> (<span class="gene" id="17203757-1-62-70">TNFalpha</span>) has been proven to be very effective in the perfusional treatment of advanced soft tissue limb <span class="disease" id="17203757-1-167-174">sarcoma</span> both in terms of tumor necrosis and limb conservative surgery rate.